Literature DB >> 11551402

Upregulation of caveolin in multidrug resistant cancer cells: functional implications.

Y Lavie1, G Fiucci, M Liscovitch.   

Abstract

Multidrug resistance (MDR) is a multifactorial process that involves elevated expression of drug transporters as well as additional biochemical changes that contribute to the drug resistant phenotype. Here we review recent results indicating the upregulation of constituents of rafts and caveolae, including glucosylceramide, cholesterol and caveolin-1, in MDR cells. Accordingly, the number of plasma membrane caveolae is greatly increased in MDR cells. The relationship between caveolin and MDR may be linked to the function of caveolin-1 in mediating cholesterol efflux, a pathway that we hypothesized to facilitate the delivery of drugs from intracellular compartments to plasma membrane resident drug transporters. An additional link seems to exist between the upregulation of GlcCer synthase and attenuation of ceramide-mediated apoptotic signaling. These adaptations may promote cell survival during chemotherapy and, hence, would be positively selected during cell exposure to cytotoxic drugs. However, the overexpression of caveolin-1, an oncosuppressive protein, may also reverse or attenuate important aspects of the phenotypic transformation of MDR cells. The molecular mechanisms by which caveolin-1 exerts its effects on cell proliferation, cell survival, and multidrug resistance remain to be fully elucidated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551402     DOI: 10.1016/s0169-409x(01)00144-2

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  19 in total

1.  Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Salahaldin A Tahir; Ziding Feng; Erika M Kwon; Elaine A Ostrander; Timothy C Thompson; Janet L Stanford
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

2.  Expression of caveolin-1 and caveolin-2 in the human pituitary: an immunohistochemical study.

Authors:  Fabio Rotondo; Eva Horvath; Kalman Kovacs; David C Bell; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway.

Authors:  Casey Trimmer; Diana Whitaker-Menezes; Gloria Bonuccelli; Janet N Milliman; Kristin M Daumer; Andrew E Aplin; Richard G Pestell; Federica Sotgia; Michael P Lisanti; Franco Capozza
Journal:  Cancer Res       Date:  2010-08-13       Impact factor: 12.701

4.  Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.

Authors:  Melanie Herzog; Caroline Henrike Storch; Philipp Gut; Dimitry Kotlyar; Joachim Füllekrug; Robert Ehehalt; Walter Emil Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-10       Impact factor: 3.000

5.  Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines.

Authors:  Parmanand Malvi; Balkrishna Chaube; Vimal Pandey; Maleppillil Vavachan Vijayakumar; Purushotham Reddy Boreddy; Naoshad Mohammad; Shivendra Vikram Singh; Manoj Kumar Bhat
Journal:  Mol Oncol       Date:  2014-11-26       Impact factor: 6.603

6.  Role of Caveolin-1 in Indomethacin-induced Death of Human Hepatoadenocarcinoma SK-Hep1 Cells.

Authors:  Kyung-Nam Kim; Ju-Hee Kang; Sung-Vin Yim; Chang-Shin Park
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

Review 7.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

8.  Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase.

Authors:  Kelly M Bailey; Jun Liu
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

Review 9.  Clinical implications of caveolins in malignancy and their potential as therapeutic targets.

Authors:  Ila Tamaskar; Ming Zhou
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

10.  Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs.

Authors:  Nuno Bernardes; Ana Rita Garizo; Sandra N Pinto; Bernardo Caniço; Catarina Perdigão; Fábio Fernandes; Arsenio M Fialho
Journal:  Cell Cycle       Date:  2018-08-04       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.